CorMedix (CRMD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.19
- Estimate
- -$0.11
- Surprise
- -65.2%
- Revenue (period 2026-09-30)
- $54.5M
- Score at report (before → after)
- 7.6 → 7.0/10
Revenue source: xbrl.
How the report landed
CorMedix (CRMD) reported a wider loss than forecast — adjusted EPS of -$0.19 against the -$0.11 estimate (a 65.2% shortfall). TrendMatrix's engine moved from Buy (Wait) (7.6/10) to Hold at 7.0/10 after the report.
Coverage in the report window
- Cormedix Q3 2026 Earnings Call Transcript — benzinga, 2026-11-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRMD Hold at 7.0/10.
1 of the last 4 quarters beat the estimate; this quarter's -65.2% surprise compares with a -46.5% four-quarter average.
What argues against it
- Concentration risk — Customer: top three customers (79.0%)
- DATA_ISSUE: analyst_target_implausible (raw $15.60 vs price $4.84 — ratio 3.2×). Rejected, falling back to technical TP.
- Cyclical trap - fwd PE 14x vs trail 2x (5.9x)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.84
- Price target
- $8.18
- Stop
- $4.68
- Upside to target
- +69.0%
Forward estimates sit below the trailing run-rate (13.8× forward vs 2.4× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 18 — a level conventionally read as oversold; trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.
CRMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $384.7M
- P/E (fwd)
- 13.8
- P/E (ttm)
- 2.4
- 52-week range
- $4.82–$13.02
- Off 52-week high
- 62.8%
- RSI (14)
- 18
- Volume vs avg
- 1.86×
- Score today
- 7.0/10